Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Ensem Therapeutics
AstraZeneca
Genmab
PMV Pharmaceuticals, Inc
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
STORM Therapeutics LTD
Assiut University
University of Chicago
Genmab
University of Southern California
University of Michigan Rogel Cancer Center
Tubulis GmbH
Eli Lilly and Company
Neonc Technologies, Inc.
Rutgers, The State University of New Jersey
Ipsen
Sumitomo Pharma America, Inc.
Terremoto Biosciences Inc.
Bristol-Myers Squibb
PT. Prodia Stem Cell Indonesia
University of Washington
Sichuan Enray Pharmaceutical Sciences Company
NYU Langone Health
Merus B.V.
Arvinas Inc.
Aulos Bioscience, Inc.
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Exscientia AI Limited
University of Arizona
Betta Pharmaceuticals Co., Ltd.
Theravectys S.A.
Amgen
University of California, Davis
One-carbon Therapeutics AB
Takeda
Kidney Cancer Research Bureau
Xinqiao Hospital of Chongqing
Xinqiao Hospital of Chongqing
Perspective Therapeutics
Radiopharm Theranostics, Ltd
Second Life Therapeutics
Onchilles Pharma Inc
M.D. Anderson Cancer Center
Ocellaris Pharma, Inc.
Eli Lilly and Company